People

Jeffrey A. Hermanson

Partner

Hermanson, Jeffrey A.
Jeffrey Hermanson is an experienced corporate lawyer whose practice focuses on representing public and private companies in all aspects of mergers and acquisitions. He has provided guidance, developed and implemented business-focused strategies, and has handled numerous complex transactions for a variety of clients, particularly those in the life sciences and technology sectors. Mr. Hermanson has advised on numerous divisional transactions, and acquisitions and dispositions of public and private companies.

Honors & Awards

  • LMG Life Sciences selected the firm as winner of its “Canadian Impact Deals of the Year” in 2013 award for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.

Publications & News

View

December 5, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement.

November 29, 2017

WilmerHale Represents Akamai in Acquisition of Nominum

Akamai Technologies, Inc. announced the company completed its acquisition of Nominum, a provider of DNS-based security solutions supporting many of the world's leading carriers.

August 14, 2017

WilmerHale Counsels Investors Abingworth Bioventures and Atlas Venture in IFM Therapeutics Acquisition by Bristol-Myers Squibb

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

July 24, 2017

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Emergent BioSolutions announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million.

June 29, 2017

WilmerHale Represents Progress in Acquiring Kinvey, the Leader in Backend as a Service (BaaS) Technology

Progress announced it has acquired Kinvey, a privately held company based in Boston and leader in Backend as a Service technology. This acquisition is a key part of the Progress strategy to provide the best platform to build and deliver modern cognitive-first applications.

April 4, 2017

Progress Buys DataRPM for $30M to Build Business Apps

Progress Software, the leading provider of application development and deployment technologies, announced it has completed a $30 million acquisition of DataRPM, a privately held company and leader in cognitive predictive maintenance for the industrial IoT market.

April 3, 2017

WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately-held rare disease company, today announced that Sucampo has acquired Vtesse for upfront consideration of $200 million.

February 2, 2017

PAREXEL Announces Definitive Agreement to Acquire The Medical Affairs Company

WilmerHale is serving as legal counsel for PAREXEL in this transaction, with Jeff Hermanson leading the team that includes Julie Fogarty, Scott Kilgore and Julie Hogan Rodgers.

December 23, 2016

WilmerHale Represents PerkinElmer in Selling Medical Imaging Business

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced its intent to sell its Medical Imaging business, a supplier of flat panel X-ray detectors that serve as components for industrial, medical and dental X-ray imaging systems, to Varian Medical Systems.

December 21, 2016

WilmerHale Represents Akamai Technologies in Acquiring Cyberfend

The WilmerHale deal team was led by Partner Hal Leibowitz and included Partner Jeffrey Hermanson and Associate Alex Civetta.

Speaking Engagements

Recent Highlights

Representation of:

  • The Medicines Company in its acquisition of Incline Therapeutics
  • Acorda Therapeutics in its acquisition of Neuronex, Inc.
  • Nabriva Therapeutics in its transaction with Forest Laboratories
  • Prism Pharmaceuticals, Inc. in its sale to Baxter Healthcare Corporation
  • Akamai Technologies, Inc. in its acquisition of Verivue, Inc.
  • SkillSoft plc in its acquisition of Thomson Learning's NETg Business
  • GloNav Inc. in its sale to NXP Semiconductors
  • Parexel in its acquisition of APEX International Clinical Research
  • Alnylam Pharmaceuticals in the sale of its German operations to Roche
  • GlycoFi Inc. in its sale to Merck & Co., Inc.
  • Xanthus Inc. in its sale to Antisoma Research Limited
  • Intercontinental Real Estate in its acquisition of Marine Lumber Company
  • Nationwide Health Properties in its acquisition of Epoch Senior Living
  • Rolls Royce Naval Marine in its acquisition of Seaworthy Systems, Inc.
  • Berkshire Mortgage Finance in its acquisition by Deutsche Bank

Practices

Skip Navigation Links.

Education

JD, cum laude, Boston University School of Law, 1984

BA, magna cum laude, Colby College, 1981, Phi Beta Kappa

Bar Admissions

Massachusetts

Skip Navigation Links.